US drug regulator blocks Regeneron’s blood cancer therapy
The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.
Drugs
Health
Pharma
Drugs
Health
Medical
Global cancer cases set to surge by 77% by 2050, new report warns
HQ Team February 6, 2024: A projection from the Global Cancer Observatory suggests that new cancer cases worldwide are set to surge by.